Literature DB >> 15154702

Sentinel node biopsy in male breast cancer.

Concetta De Cicco1, Silvia M Baio, Paolo Veronesi, Giuseppe Trifirò, Antonio Ciprian, Annarita Vento, Joel Rososchansky, Giuseppe Viale, Giovanni Paganelli.   

Abstract

OBJECTIVE: Male breast cancer is a rare disease and axillary status is the most important prognostic indicator. Lymphoscintigraphy associated with gamma-probe guided surgery has been proved to reliably detect sentinel nodes in female patients with breast cancer. This study evaluates the feasibility of the surgical identification of sentinel node by using lymphoscintigraphy and a gamma-detecting probe in male patients, in order to select subjects who would be suitable for complete axillary lymphadenectomy.
METHODS: Colloid human albumin labelled with 99Tc was administered to 18 male patients with breast cancer and clinically negative axillary lymph nodes. Lymphoscintigraphy was performed the day before surgery. An intraoperative gamma-detecting probe was used to identify sentinel nodes during surgery.
RESULTS: Lymphoscintigraphy and biopsy of the sentinel node were successful in all cases. A total of 20 sentinel nodes were removed. Pathological examinations showed 11 infiltrating ductal carcinomas, two intraductal carcinomas and five intracystic papillary carcinomas. Six patients (33%) had positive sentinel node (micrometastases were found in three patients). These patients underwent axillary dissection; in five of them (83%) the sentinel node was the only positive node. Twelve patients (67%) showed negative sentinel nodes; in all of them no further surgical treatments were planned.
CONCLUSIONS: As in women, lymphoscintigraphy and sentinel node biopsy under the guidance of a gamma-detecting probe proved to be an easy method for the detection of sentinel nodes in male breast carcinoma. In male patients with early stage cancer, sentinel node biopsy might represent the standard surgical procedure in order to avoid unnecessary morbidity after surgery, preserving accurate staging of the disease in the axilla.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154702     DOI: 10.1097/00006231-200402000-00008

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

Review 1.  Sentinel node detection in pre-operative axillary staging.

Authors:  Giuseppe Trifirò; Giuseppe Viale; Oreste Gentilini; Laura Lavinia Travaini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-22       Impact factor: 9.236

2.  The Management and Outcomes of Male Breast Cancer.

Authors:  Ömer Uslukaya; Metehan Gümüş; Hatice Gümüş; Zübeyir Bozdağ; Ahmet Türkoğlu
Journal:  J Breast Health       Date:  2016-10-01

Review 3.  Male breast carcinoma: increased awareness needed.

Authors:  Jonathan White; Olive Kearins; David Dodwell; Kieran Horgan; Andrew M Hanby; Valerie Speirs
Journal:  Breast Cancer Res       Date:  2011-09-29       Impact factor: 6.466

4.  [Breast cancer in men: about 6 cases].

Authors:  Kamilia Laabadi; Sofia Jayi; Fatimazohra Fdili Alaoui; Hakima Bouguern; Hikmat Chaara; My Abdelilah Melhouf; Karim Ibn Majdoub Hassani; Said Ait Laalim; Hicham Anoun; Imane Toughrai; Khalid Mazaz
Journal:  Pan Afr Med J       Date:  2013-10-28

5.  Intracystic papillary carcinoma in the male breast: a rare endpoint of a wide spectrum.

Authors:  Ketan Vagholkar; Khojasteh Dastoor; Indumati Gopinathan
Journal:  Case Rep Oncol Med       Date:  2013-08-26

6.  Computed tomographic lymphography for sentinel lymph node biopsy in male breast cancer: report of two cases.

Authors:  Naoki Hashimoto; Yurie Kudo; Michihiro Kurushima; Yamato Suzuki; Takafumi Yachi; Tomohisa Tokura; Yutaka Umehara; Shinsuke Nishikawa; Kenichi Takahashi; Takayuki Morita; Fumiko Narita
Journal:  Springerplus       Date:  2013-07-29

Review 7.  Current state of surgical management for male breast cancer.

Authors:  Vladimir Popa-Nimigean; Muneer Ahmed
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.